I was very surprised to see in an issue of the NEJM earlier this year that Loxo Oncology had developed a selective TRK inhibitor, larotrectinib, and even more surprised to learn that TRK fusions occur in about 1 percent of all human cancers.
New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.
